Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential

Andy Chen, an analyst from Wolfe Research, maintained the Buy rating on Immunovant. The associated price target is $47.00.

Andy Chen has given his Buy rating due to a combination of factors that strengthen confidence in IMVT-1402’s Phase 3 Graves’ disease program. He underscores that thyroid‑stimulating antibodies sit at the top of the disease cascade for most Graves’ patients, so directly lowering these antibodies with an FcRn inhibitor should reliably restore thyroid balance and reduce downstream inflammation, unlike current indirect therapies.

He also highlights that the Phase 3 Graves’ trial uses tighter patient selection and a TRAb‑based inclusion criterion, making the study population closely resemble the successful Phase 2 cohort and less like the more heterogeneous TED population. In addition, Chen notes that Roivant has now treated roughly twice as many hyperthyroid patients with FcRn‑targeting agents and consistently achieved about an 80% normalization rate in thyroid hormones, reinforcing the reproducibility and commercial potential that underpin his Buy recommendation.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $42.00 price target.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMVT in relation to earlier this year.